Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Fate Therapeutics (FATE) over the last 14 years, with Q3 2025 value amounting to $21.3 million.

  • Fate Therapeutics' Cash from Investing Activities fell 1645.26% to $21.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $106.4 million, marking a year-over-year increase of 20600.49%. This contributed to the annual value of $12.2 million for FY2024, which is 8915.55% down from last year.
  • According to the latest figures from Q3 2025, Fate Therapeutics' Cash from Investing Activities is $21.3 million, which was down 1645.26% from $19.6 million recorded in Q2 2025.
  • Over the past 5 years, Fate Therapeutics' Cash from Investing Activities peaked at $80.4 million during Q3 2022, and registered a low of -$471.9 million during Q1 2021.
  • For the 5-year period, Fate Therapeutics' Cash from Investing Activities averaged around $2.7 million, with its median value being $24.8 million (2023).
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first tumbled by 208489.11% in 2021, then skyrocketed by 303637.03% in 2022.
  • Fate Therapeutics' Cash from Investing Activities (Quarter) stood at $71.3 million in 2021, then fell by 25.49% to $53.1 million in 2022, then decreased by 14.61% to $45.4 million in 2023, then tumbled by 49.69% to $22.8 million in 2024, then fell by 6.77% to $21.3 million in 2025.
  • Its Cash from Investing Activities was $21.3 million in Q3 2025, compared to $19.6 million in Q2 2025 and $42.7 million in Q1 2025.